Celularity Inc. (NASDAQ:CELUW – Get Free Report) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,342 shares, an increase of 350.4% from the April 15th total of 742 shares. Based on an average trading volume of 7,256 shares, the days-to-cover ratio is presently 0.5 days.
Celularity Trading Down 0.6%
NASDAQ:CELUW opened at $0.01 on Wednesday. The stock has a fifty day moving average price of $0.01 and a 200-day moving average price of $0.01. Celularity has a fifty-two week low of $0.01 and a fifty-two week high of $0.08.
Celularity Company Profile
Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.
Featured Stories
- Five stocks we like better than Celularity
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
